Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
Luuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 5, pp. e338-e350
Open Access | Times Cited: 111

Showing 1-25 of 111 citing articles:

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
Rona Smith, Rachel Jones, Ulrich Specks, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 7, pp. 937-944
Open Access | Times Cited: 61
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
Yijia Li, Manish C. Choudhary, James Regan, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 731
Open Access | Times Cited: 48
The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future
Andrea Antinori, Mary T. Bausch-Jurken
The Journal of Infectious Diseases (2023) Vol. 228, Iss. Supplement_1, pp. S4-S12
Open Access | Times Cited: 44
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis
Xi Wu, Lu Wang, Lu Shen, et al.
EBioMedicine (2022) Vol. 81, pp. 104102-104102
Open Access | Times Cited: 51
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
Laura Boekel, Eileen W Stalman, Luuk Wieske, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 6, pp. e417-e429
Open Access | Times Cited: 50
COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study
Malcolm Risk, Salim S. Hayek, Elena Schiopu, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 11, pp. e775-e784
Open Access | Times Cited: 48
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases
Roya Monica Dayam, Jaclyn C. Law, Rogier Goetgebuer, et al.
JCI Insight (2022) Vol. 7, Iss. 11
Open Access | Times Cited: 44
Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
Xuan Wang, Katrin Haeussler, Anne Spellman, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 28
Third and Fourth Vaccine Doses Broaden and Prolong Immunity to SARS-CoV-2 in Adult Patients with Immune-Mediated Inflammatory Diseases
Michelle W. Cheung, Roya M. Dayam, Janna R. Shapiro, et al.
The Journal of Immunology (2023) Vol. 211, Iss. 3, pp. 351-364
Open Access | Times Cited: 23
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial
Eliza F. Chakravarty, Tammy O. Utset, Diane L. Kamen, et al.
The Lancet Rheumatology (2024) Vol. 6, Iss. 3, pp. e168-e177
Closed Access | Times Cited: 10
Pathophysiology, diagnosis, and management of neuroinflammation in covid-19
Rachel Brown, Laura Benjamin, Michael P. Lunn, et al.
BMJ (2023), pp. e073923-e073923
Open Access | Times Cited: 20
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations
Koos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
Journal of Autoimmunity (2023) Vol. 135, pp. 102984-102984
Open Access | Times Cited: 18
Effect of DMARDs on the immunogenicity of vaccines
Yannick van Sleen, Kornelis S. M. van der Geest, Anke Huckriede, et al.
Nature Reviews Rheumatology (2023) Vol. 19, Iss. 9, pp. 560-575
Closed Access | Times Cited: 18
Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
S Kavikondala, Katrin Haeussler, Xuan Wang, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 7, pp. 1419-1438
Open Access | Times Cited: 6
A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: A position paper of the American College of Allergy, Asthma and Immunology
Phil Lieberman, Derek K. Chu, Tasnuva Ahmed, et al.
Annals of Allergy Asthma & Immunology (2024) Vol. 133, Iss. 3, pp. 286-294
Open Access | Times Cited: 5
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies
G. Olivieri, Donato Amodio, Emma Concetta Manno, et al.
Vaccine (2025) Vol. 51, pp. 126853-126853
Open Access
Evolution of SARS-CoV-2 antibody repertoire after successive mRNA vaccinations under immunosuppressive treatment
Jim Keijser, Eileen W Stalman, Luuk Wieske, et al.
EBioMedicine (2025) Vol. 113, pp. 105620-105620
Closed Access
Early suPAR levels as a predictor of COVID-19 severity: A new tool for efficient patient triage
Pauline Nègre, Didier Tayac, Thibaut Jamme, et al.
Infectious Diseases Now (2025), pp. 105058-105058
Open Access
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002417-e002417
Open Access | Times Cited: 24
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases
Luuk Wieske, Laura Kummer, Koos P J van Dam, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 23
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls
Felix Kartnig, Daniel Mrak, Elisabeth Simader, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 292-300
Open Access | Times Cited: 22
A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations
Lidan Hu, Jingmiao Sun, Yan Wang, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1045-1045
Open Access | Times Cited: 12
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis
Pedro Martínez‐Fleta, Esther F. Vicente‐Rabaneda, Ana Triguero‐Martínez, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 4
Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases
Ruth Xian Lynn Yap, Yi Wye Lai, Chang Wei, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 274-274
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top